Similar articles

• Practical management of patients with chronic myeloid leukemia receiving imatinib.

  Deininger MW, O'Brien SG, Ford JM, Druker BJ. Deininger MW, et al. J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13. J Clin Oncol. 2003. PMID: 12668652 Review.
• Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.

  Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S. Khan KA, et al. J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8. J Coll Physicians Surg Pak. 2008. PMID: 18460249
• Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.

  Tóthová E, Kafková A, Fricová M, Benová B, Kirschnerová G, Tóthová A. Tóthová E, et al. Neoplasma. 2005;52(1):63-7. Neoplasma. 2005. PMID: 15739029 Clinical Trial.
• Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.

  Reksodiputro AH, Syafei S, Prayogo N, Karsono B, Rinaldi I, Rajabto W, Mulansari NA. Reksodiputro AH, et al. Acta Med Indones. 2010 Jan;42(1):2-5. Acta Med Indones. 2010. PMID: 20305324
• Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.

  Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Kolb EA, et al. Cancer. 2003 Dec 15;98(12):2643-50. doi: 10.1002/cncr.11895. Cancer. 2003. PMID: 14669284 Review.